13141-92-9 Usage
Chemical structure
A urea molecule with a substituted phenyl group, consisting of a urea backbone with an ethoxyphenyl group at the 1 position and a fluorophenyl group at the 3 position.
Molecular weight
Approximately 260.26 g/mol
Appearance
Likely a solid, although the exact physical state is not provided in the material.
Potential applications
Medicine and pharmaceuticals, specifically in the development of new drugs or as a research tool in understanding biological processes.
Unique structure
The specific substitution pattern of the ethoxyphenyl and fluorophenyl groups may impart unique physiological effects.
Field of interest
Pharmacology and medicinal chemistry, due to its potential for understanding biological processes and the development of new drugs.
Chemical properties
The material does not provide specific information on the chemical properties, but it can be inferred that the compound may have unique reactivity or stability due to its substitution pattern.
Research significance
The compound's unique structure and potential applications make it a valuable subject for further research in the fields of pharmacology and medicinal chemistry.
Safety and handling
The material does not provide specific information on safety and handling, but as with any chemical compound, it is important to follow proper safety protocols and guidelines when working with 1-(4-ethoxyphenyl)-3-(3-fluorophenyl)urea.
Check Digit Verification of cas no
The CAS Registry Mumber 13141-92-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,1,4 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 13141-92:
(7*1)+(6*3)+(5*1)+(4*4)+(3*1)+(2*9)+(1*2)=69
69 % 10 = 9
So 13141-92-9 is a valid CAS Registry Number.
13141-92-9Relevant academic research and scientific papers
DIARYL UREAS AS CB1 ANTAGONISTS
-
Page/Page column 59, (2008/06/13)
Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.
